RWD130 Elacestrant vs Everolimus + Exemestane in Patients With ER+/HER2- ESR1-Mutated Advanced/Metastatic Breast Cancer (mBC) With Prior Endocrine Therapy + CDK4/6 Inhibitor ≥12 Months: Combining Real-World and Clinical Trial Data
Year: 2024
Type: conference-abstract
Source: Value in Health
Authors: F. Felizzi, E. Fenu, S. Kloss, V. Laizet, P. Le Nouveau, S. Moreno
Institution: Menarini Group (Italy)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4405751012